Drug intelligence / Profile preview

mRNA-1083.2

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

mRNA-1083.2 is a second-generation combination vaccine candidate developed by Moderna that combines the company's COVID-19 vaccine (mRNA-1283) with an influenza vaccine (mRNA-1010). It is designed to provide protection against both COVID-19 caused by SARS-CoV-2 and influenza virus infections caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains. The vaccine is administered via intramuscular injection and is currently in late-stage clinical development.

Other names: COVID+Flu vaccine - Moderna TherapeuticsmRNA-1083mRNA1083mRNA 1083

Beyond the preview

Go deeper on mRNA-1083.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1083.2.

Explore the full profile